T he scientific understanding of the relationship between diet and disease has progressed greatly in the past decades. With this growing scientific evidence supporting the important role of diet in modifying the risks of some chronic diseases, there is increasing consumer and marketing interest in nutrition and health. The Health Products and Food Branch has been actively involved in this issue through both policy and regulatory development and extensive public and scientific consultations. Feedback from the public consultations has been generally supportive of scientifically valid diet-related health claims for foods but mixed with regard to product-specific claims. Health Canada is moving ahead in this regard to find a solution that best matches public needs and legal constraints.
Following two years of consultation, Health Canada published a policy recommendation on health claims for foods in November 1998. The policy recommended that structure/ function and risk reduction claims be permitted for foods, and that the claims may be generic or product-specific.
The definition of a drug in the Food and Drugs Act is far-reaching as it includes any substance(s) manufactured, sold or represented for use in the prevention or treatment of disease or in modifying organic function. This means foods bearing risk reduction claims or many structure/function claims would likely fall within the definition of a drug. In addition, subsections 3 (1) and 3 (2) of the Food and Drugs Act prohibit the sale of a food or a drug that is advertised to the general public or labelled as a treatment, preventative or cure of any of the diseases listed in Schedule A to the Act. Schedule A lists many of the major diet-related chronic diseases. It should be noted that this prohibition of treatment / prevention claims for these diseases applies even if the claims are true. Section 3 dates from 1934 and was intended to protect the public at a time when there were no effective treatments for many diseases.
To enable the use of risk reduction claims for foods, another Section of the Food and Drugs Act was applied. Section 30 of the Act allows the Governor-in-Council to make regulations exempting any food or drug from the provisions of the Act. Under this authority, foods bearing a diet-related health claim could be exempted from the prohibition contained in Section 3 and the provisions related to drugs provided certain conditions are met.
To provide more opportunities for communicating information about the role of diet in disease, risk reduction, and the health benefits of foods to consumers in labelling and advertising, Health Canada has proposed five generic health claims for adoption in Canada. This followed an initial review of the issues and extensive review of the scientific basis of the proposed claims. The five generic health claims are: 1. "A healthy diet containing foods high in potassium and low in sodium may reduce the risk of high blood pressure, a risk factor for stroke and heart disease." 2. "A healthy diet with adequate calcium and vitamin D, and regular physical activity, help to achieve strong bones and may reduce the risk of osteoporosis." 3. "A healthy diet low in saturated and trans fats may reduce the risk of heart disease." 4. "A healthy diet rich in a variety of vegetables and fruits may help reduce the risk of some types of cancer." 5. " Does not promote tooth decay."
Regulatory amendments concerning these five diet-related claims were published in Canada Gazette Part I, on June 16, 2001. The proposed regulatory amendments specify that the food must meet prescribed criteria for composition and labelling. The claims will emphasize a "whole-diet" approach rather than one that is food-specific.
Once a generic health claim is authorized after publication in Canada Gazette Part II, any food that meets the specified conditions for composition and labelling may carry the claim without further assessment. Additional claims would be possible following a similar process of submission, review, and an amendment to the regulations. The Federal Regulatory Process is described in a publication, Guide to the Regulatory Process, available on the Privy Council Office website (http://www.pco-bcp.gc.ca).
In the case of product-specific claims, if a food were to carry a treatment/prevention claim or certain structure/function claims, it would fall within the definition of a drug under the Food and Drugs Act, and the product would be subject to the provisions of the Act and its Regulations with respect to drugs. The proposal of Stephen et al. in this issue of the journal 1 is that foods with health claims be regulated under a new subsection of the Drug Regulations by a process similar to that used for low risk drugs. The claim for the bioactive constituent would be supported by a product monograph (a factual, scientific document that describes the properties, claims, indications for, and conditions of use of the bioactive constituent and other information that may be required for its safe and effective use). Stephen et al. also propose that these Foods with Health Claims would be exempt from the prohibitions contained in section 3 by utilizing section 30 of the Act.
It is not clear that this approach is an expedient solution to conveying health messages regarding foods and their components. A number of issues are apparent. First, Health Canada agrees with Stephen et al. that since the product is actually a food, it is considered most important from a safety perspective (microbiological, chemical, toxicological, viral, etc.) that the product be regulated as a food. There are difficulties in trying to regulate a product under both the Food Regulations and the Drug Regulations. For example, the two sets of Regulations have different requirements for some areas, such as purity specifications and labelling.
A second issue is exempting food products from the prohibition against claims related to Schedule A diseases (i.e., permitting claims for Schedule A diseases). To provide a "level playing field", such a blanket exemption would likely have to be extended also to natural health products and OTC drugs. Before any changes are contemplated to the application of section 3 and Schedule A, there would have to be a full discussion of the pros and cons with all interested parties. In the meantime, Health Canada will continue to consider carefully all exemptions to section 3 based on the benefit to Canadians as was done in the case of the diet-related health claims.
Health Canada recently published a proposed framework for regulating structure/function claims for foods (http://www.hc-sc.gc.ca/food-aliment/nssc/ne-en/health_claims-allegations_sante/ pdf/e_finalproposal.pdf). The proposal is analogous to that of Stephen et al. such that for each approved structure/function claim for a specific food product, a Claim Identification Number would be given. Such products would be regulated as foods, and would be exempt from the Drug Regulations. The process of approval would be much more efficient than changing the Food Regulations for each new claim.
Health Canada continues to consider options for informing the public about the health benefits of diet. Interested parties have indicated some concerns with Health Canada's proposed regulatory framework for product-specific authorization of health claims for foods. On one hand, the food industry, while generally supportive of the proposal in principle, is critical of the lack of provision for product-specific risk reduction claims for schedule A diseases. In addition, the food industry questions at what point a series of approved productspecific claims based on one bioactive ingredient would become a generic claim. On the other hand, health professionals and health organizations expressed concerns that product-specific claims suggest an over-simplistic approach to addressing major chronic diseases, and also that these claims undermine healthy eating messages. While health professionals and health organizations are concerned with productspecific claims in general, they are supportive of the proposal to restrict the claims to non-Schedule A diseases.
Health Canada will continue to evaluate the issues and options to identify feasible means to provide opportunities to communicate the role of diet in disease risk reduction and at the same time encourage marketing interest in nutrition and health. 
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Les aliments visés par des allégations santé : l'initiative réglementaire de Santé Canada
Diane Gorman L es connaissances scientifiques de la relation entre l'alimentation et les maladies ont beaucoup progressé ces dernières décennies. La preuve scientifique du rôle important de l'alimentation dans l'atténuation des risques de certaines maladies chroniques croît sans cesse, tout comme l'intérêt des consommateurs et des spécialistes du marketing pour la nutrition et la santé. La Direction générale des produits de santé et des aliments est l'un des intervenants les plus actifs dans ce dossier, de par les politiques et règlements qu'elle a élaborés et les vastes consultations publiques et scientifiques qu'elle a menées. Le public appuie dans l'ensemble les allégations diététiques relatives à la santé, tant qu'elles reposent sur des données scientifiques éprouvées, mais les allégations spécifiques à un produit ne font pas consensus. Santé Canada s'efforce donc de trouver une solution qui réponde aux besoins du public tout en respectant les contraintes juridiques.
En novembre 1998, après deux ans de consultations, Santé Canada publiait une recommandation de principe sur les allégations santé visant les aliments. On y recommandait de permettre les allégations relatives aux effets des produits alimentaires sur une structure ou une fonction du corps et sur la réduction du risque, que ces allégations soient générales ou spécifiques à un produit.
La définition d'une drogue dans la Loi sur les aliments et drogues va très loin : elle s'étend à toute substance fabriquée, vendue ou présentée comme pouvant servir à la prévention ou au traitement d'une maladie ou à la modification de fonctions organiques. Par conséquent, les aliments visés par une allégation relative à la réduction du risque, et de nombreuses allégations relatives aux effets structurels ou fonctionnels, pourraient entrer dans cette définition. En outre, les paragraphes 3(1) et 3(2) de la Loi sur les aliments et drogues interdisent la vente d'un aliment ou d'une drogue représenté par une éti-quette, ou dont la publicité a été faite auprès du grand public, à titre de traitement, de mesure préventive ou de moyen de guérison d'une maladie énumérée à l'annexe A de la Loi. Or, l'annexe A énumère bon nombre des grandes maladies chroniques d'origine alimentaire. Les alléga-tions de traitement ou de prévention des maladies sont interdites même lorsqu'elles sont véridiques. L'article 3 date de 1934; il visait à protéger le public à une époque où il n'existait aucun traitement efficace à de nombreuses maladies.
Pour permettre l'utilisation d'allégations relatives aux effets de produits alimentaires sur la réduction du risque, on a recours à un autre article de la Loi sur les aliments et drogues. Selon l'article 30, le gouverneur en conseil peut, par règlement, exempter un aliment ou une drogue de l'application de la Loi. Ainsi, à condition de respecter certains critères, les aliments visés par une allégation santé peuvent être exemptés de
